Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N P Brenwald

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Antimicrobial Chemotherapy|January 1, 1991
Mechanism of nitrofuran resistance in Salmonella enteritidis phage type 4 and interpretation of nitrofuran susceptibility testsD F Brown, R Upson, N P Brenwald, et al.
The Journal of Antimicrobial Chemotherapy|March 1, 1997
Susceptibility testing of fastidious organismsJ M Andrews, N Hadley, N P Brenwald, et al.
The Journal of Antimicrobial Chemotherapy|March 5, 2003
A multidrug efflux phenotype mutant of Streptococcus pyogenesH E Jones, N P Brenwald, K A Owen, et al.
Journal of Clinical Pathology|July 1, 1990
Selective medium for isolating Arcanobacterium haemolyticumN P Brenwald, E L Teare, L K Mountfort, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1997
In vitro activity of BAY 12-8039, a new fluoroquinoloneJ M Woodcock, J M Andrews, F J Boswell, et al.
The Journal of Antimicrobial Chemotherapy|December 31, 1997
Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopyJ M Andrews, D Honeybourne, G Jevons, et al.
The Journal of Antimicrobial Chemotherapy|January 1, 1997
The in-vitro activity of faropenem, a novel oral penemJ M Woodcock, J M Andrews, N P Brenwald, et al.
The Journal of Antimicrobial Chemotherapy|April 2, 2004
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492S J Harnett, A P Fraise, J M Andrews, et al.
The Journal of Antimicrobial Chemotherapy|June 1, 1997
Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopyJ M Andrews, D Honeybourne, N P Brenwald, et al.
The Journal of Antimicrobial Chemotherapy|March 3, 1999
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agentF J Boswell, J M Andrews, J P Ashby, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Antimicrobial Chemotherapy|January 1, 1991
Mechanism of nitrofuran resistance in Salmonella enteritidis phage type 4 and interpretation of nitrofuran susceptibility testsD F Brown, R Upson, N P Brenwald, et al.
The Journal of Antimicrobial Chemotherapy|March 1, 1997
Susceptibility testing of fastidious organismsJ M Andrews, N Hadley, N P Brenwald, et al.
The Journal of Antimicrobial Chemotherapy|March 5, 2003
A multidrug efflux phenotype mutant of Streptococcus pyogenesH E Jones, N P Brenwald, K A Owen, et al.
Journal of Clinical Pathology|July 1, 1990
Selective medium for isolating Arcanobacterium haemolyticumN P Brenwald, E L Teare, L K Mountfort, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1997
In vitro activity of BAY 12-8039, a new fluoroquinoloneJ M Woodcock, J M Andrews, F J Boswell, et al.
The Journal of Antimicrobial Chemotherapy|December 31, 1997
Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopyJ M Andrews, D Honeybourne, G Jevons, et al.
The Journal of Antimicrobial Chemotherapy|January 1, 1997
The in-vitro activity of faropenem, a novel oral penemJ M Woodcock, J M Andrews, N P Brenwald, et al.
The Journal of Antimicrobial Chemotherapy|April 2, 2004
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492S J Harnett, A P Fraise, J M Andrews, et al.
The Journal of Antimicrobial Chemotherapy|June 1, 1997
Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopyJ M Andrews, D Honeybourne, N P Brenwald, et al.
The Journal of Antimicrobial Chemotherapy|March 3, 1999
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agentF J Boswell, J M Andrews, J P Ashby, et al.
Pageof 3